SEC Form 4 · accession 0001562180-18-004318
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gil J Van Lunsen
Director
Period of report
Oct 25, 2018
Accepted (ET)
Oct 29, 2018 · 6:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 26, 2018 | M | 5,000 | — | A | 24,297 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $14.55 | Oct 25, 2018 | A | 25,000 | A | — | Oct 25, 2028 | Common Stock | 25,000 | 25,000 | D |
| Restricted Stock UnitsF3 | $0.00 | Oct 25, 2018 | A | 5,000 | A | — | — | Common Stock | 5,000 | 5,000 | D |
| Restricted Stock UnitsF4 | $0.00 | Oct 26, 2018 | M | 5,000 | D | — | — | Common Stock | 5,000 | 0 | D |
Explanation of responses
- F1Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by Array BioPharma Inc. ("Array") on October 26, 2017, as a result of the vesting of all such RSUs.
- F2The options vest in full on October 25, 2019, subject to continued service on Array's board of directors.
- F3RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock. The RSUs vest in full and will be settled in common stock on October 25, 2019, subject to continued service on Array's board of directors.
- F4The RSUs vested and were settled in common stock on October 26, 2018.